|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis: Growth Factors for Bone, Dental, Cartilage and Tendon Repair
La Merie Publishing, Dec 2009, Pages: 42
The present Competitive Intelligence Report about growth factors for bone, dental, cartilage and tendon repair provides a competitor evaluation in the field of molecules such as proteins, peptides, antibodies and small molecules stimulating growth of bone, dental, cartilage and soft tissue such as tendons as of December 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Bone morphogenetic protein 2 (rhBMP-2) is approved by the Food and Drug Administration for anterior lumbar interbody fusion and for acute open tibial fractures; rhBMP-7, on the other hand, is approved for long bone defects and has received a humanitarian device exemption for revision posterolateral lumbar operations and recalcitrant long bone unions. The commercial success of BMP-2 has spurred the clinical evaluation in many other subsets of bone defects and the research into new growth factors and scaffolds. The first products were also approved for use in dental implantation procedures extending the scope of indications for bone and dental growth factors.
In contrast to the more advanced clinical stage development pipeline of bone and dental growth factors, the use of growth factors for cartilage and tendon or soft tissue repair still is preclinical representing a niche with a competitive advantage for the players in the field. While traditional growth factors are proteins, new molecules stimulating or accelerating growth of bone, dental, cartilage or soft tissue also are engineered peptides, antibodies, small molecules or even plasmids. Among the growth stimulators are the BMPs, GDFs, PDGF, PTH receptor agonists, FGF and many more. In many cases, selection of the appropriate scaffold for delivery of the growth stimulating molecules is essential for the success of the therapy.
The report includes a compilation of current marketed and active projects in research and development of proteins, peptides, antibodies and small molecules stimulating growth and repair of bone, dental, cartilage and soft tissue. e.g. tendon. In addition, the report lists company-specific R&D pipelines of growth factors for bone, dental, cartilage and tendon repair. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Customers who bought this item also bought
Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
Royalty Rates for Pharmaceuticals & Biotechnology, 7th Edition
Competitor Analysis: Neurotrophic Growth Factors
Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others
Drug Delivery in Cancer - Technologies, Markets and Companies
Pain Therapeutics - Drugs, Markets and Companies
Regenerative Medicine Markets
The Global Orthobiologics Market - Players, products and technologies driving change 2008
Competitor Analysis: FGF-R Agonists and Antagonists
Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?
|
|
|
|
